1qj7: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
The binding modes of four active site-directed, acylating inhibitors of, human alpha-thrombin have been determined using X-ray crystallography., These inhibitors (GR157368, GR166081, GR167088, and GR179849) are, representatives of a series utilizing a novel 5, 5-trans-lactone template, to specifically acylate Ser195 of thrombin, resulting in an acyl complex., In each case the crystal structure of the complex reveals a binding mode, which is consistent with the formation of a covalent bond between the, ring-opened lactone of the inhibitor and residue Ser195. Improvements in, potency and selectivity of these inhibitors for thrombin are rationalized, on the basis of the observed protein/inhibitor interactions identified in, these complexes. Occupation of the thrombin S2 and S3 pockets is shown to, be directly correlated with improved binding and a degree of selectivity., The binding mode of GR179849 to thrombin is compared with the, thrombin/PPACK complex [Bode, W., Turk, D., and Karshikov, A. (1992), Protein Sci. 1, 426-471] as this represents the archetypal binding mode, for a thrombin inhibitor. This series of crystal structures is the first, to be reported of synthetic, nonpeptidic acylating inhibitors bound to, thrombin and provides details of the molecular recognition features that, resulted in nanomolar potency. | The binding modes of four active site-directed, acylating inhibitors of, human alpha-thrombin have been determined using X-ray crystallography., These inhibitors (GR157368, GR166081, GR167088, and GR179849) are, representatives of a series utilizing a novel 5, 5-trans-lactone template, to specifically acylate Ser195 of thrombin, resulting in an acyl complex., In each case the crystal structure of the complex reveals a binding mode, which is consistent with the formation of a covalent bond between the, ring-opened lactone of the inhibitor and residue Ser195. Improvements in, potency and selectivity of these inhibitors for thrombin are rationalized, on the basis of the observed protein/inhibitor interactions identified in, these complexes. Occupation of the thrombin S2 and S3 pockets is shown to, be directly correlated with improved binding and a degree of selectivity., The binding mode of GR179849 to thrombin is compared with the, thrombin/PPACK complex [Bode, W., Turk, D., and Karshikov, A. (1992), Protein Sci. 1, 426-471] as this represents the archetypal binding mode, for a thrombin inhibitor. This series of crystal structures is the first, to be reported of synthetic, nonpeptidic acylating inhibitors bound to, thrombin and provides details of the molecular recognition features that, resulted in nanomolar potency. | ||
==Disease== | |||
Known diseases associated with this structure: Dysprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hyperprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hypoprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]] | |||
==About this Structure== | ==About this Structure== | ||
| Line 28: | Line 31: | ||
[[Category: trypsin like proteinase]] | [[Category: trypsin like proteinase]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 18:53:47 2007'' | ||